- « Previous
- Clinical Pharmacology
- Next »
Aciphex
Clinical Pharmacology
Aciphex
Rabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H+, K+ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton-pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion.
In gastric parietal cells, rabeprazole is protonated, accumulates, and is transformed to an active sulfenamide. When studied in vitro, rabeprazole is chemically activated at pH 1.2 with a half-life of 78 seconds. It inhibits acid transport in porcine gastric vesicles with a half-life of 90 seconds.
Antisecretory Activity
The anti-secretory effect begins within one hour after oral administration of 20 mg ACIPHEX®. The median inhibitory effect of ACIPHEX® on 24 hour gastric acidity is 88% of maximal after the first dose. ACIPHEX® 20 mg inhibits basal and peptone meal-stimulated acid secretion versus placebo by 86% and 95%, respectively, and increases the percent of a 24-hour period that the gastric pH > 3 from 10% to 65% (see table below). This relatively prolonged pharmacodynamic action compared to the short pharmacokinetic half-life (1-2 hours) reflects the sustained inactivation of the H+, K+ATPase.
Gastric Acid Parameters ACIPHEX® Versus Placebo After 7 Days of Once Daily Dosing
| Parameter | ACIPHEX® (20 mg QD) |
Placebo |
| Basal Acid Output (mmol/hr) | 0.4* | 2.8 |
| Stimulated Acid Output (mmol/hr) | 0.6* | 13.3 |
| % Time Gastric pH > 3 | 65* | 10 |
| *(p<0.01 versus placebo) | ||
Compared to placebo, ACIPHEX®, 10 mg, 20 mg, and 40 mg, administered once daily for 7 days significantly decreased intragastric acidity with all doses for each of four meal-related intervals and the 24-hour time period overall. In this study, there were no statistically significant differences between doses; however, there was a significant dose-related decrease in intragastric acidity. The ability of rabeprazole to cause a dose-related decrease in mean intragastric acidity is illustrated below.
AUC Acidity (mmol•hr/L)
ACIPHEX® Versus Placebo on Day 7 of Once Daily Dosing (mean±SD)
| AUC interval (hrs) | Treatment | |||
| 10 mg RBP (N=24) | 20 mg RBP (N=24) | 40 mg RBP (N=24) | Placebo (N=24) | |
| 08:00 – 13:00 | 19.6±21.5* | 12.9±23* | 7.6±14.7* | 91.1±39.7 |
| 13:00 – 19:00 | 5.6±9.7* | 8.3±29.8* | 1.3±5.2* | 95.5±48.7 |
| 19:00 – 22:00 | 0.1±0.1* | 0.1±0.06* | 0.0±0.02* | 11.9±12.5 |
| 22:00 – 08:00 | 129.2±84* | 109.6±67.2* | 76.9±58.4* | 479.9±165 |
| AUC 0-24 hours | 155.5±90.6* | 130.9±81* | 85.8±64.3* | 678.5±216 |
| *(p<0.001 versus placebo) | ||||
Generic Name: Rabeprazole Sodium
- « Previous
- Clinical Pharmacology
- Next »
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
GI Disorders
Get the latest treatment options.
Eating With Heartburn/Acid Reflux
If you have chronic heartburn, you are at risk for GERD. If left untreated, GERD can put you at risk for cancer of the esophagus. See more WebMD Videos »
